Felmetatug vedotin

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody
www.ebi.ac.uk
Drug name
Felmetatug vedotin
www.ebi.ac.uk

  • felmetatug vedotin
  • Felmetatug vedotin
  • Felmetatug Vedotin
  • felmetatug vedotin [INN]
  • Felmetatug vedotin [WHO-DD]
  • felmetatug vedotin inn
  • felmetatug vedotin who dd
  • h gamma1 heavy chain homo sapiens 1 450 vh homo sapiens ighv4 39 01 96 0 ighd ighj5 02 93 8 cdr imgt 10 7 12 26 35 53 59 98 109 1 120 homo sapiens ighg1 01 100 g1m17 1 ch1 k120 ch3 d12 l14 ch1 k120 217 121 218 hinge 1 15 219 233 ch2 234 343 ch3 d12 359 l14 361 344 448 chs 449 450 121 450 223 214 disulfide with l kappa light chain homo sapiens 1 214 v kappa homo sapiens igkv3 15 01 96 8 igkj4 01 91 7 cdr imgt 6 3 9 27 32 50 52 89 97 1 107 homo sapiens igkc 01 100 km3 a45 1 v101 c kappa a45 1 153 v101 191 108 214 dimer 229 229 232 232 bisdisulfide produced in chinese hamster ovary cho cells cell line cho dg44 glycoform alfa substituted at the sulfur atoms of four l cysteinyl residues on an average among 223 229 232 214 223 229 232 and 214 with a group consisting of 3rs 1 6 2s 1 2s 5 carbamoylamino 1 4 2s 1 2s 1 3r 4s 5s 1 2s 2 1r 2r 3 1s 2r 1 hydroxy 1 phenylpropan 2 yl amino 1 methoxy 2 methyl 3 oxopropyl pyrrolidin 1 yl 3 methoxy 5 methyl 1 oxoheptan 4 yl methyl amino 3 methyl 1 oxobutan 2 yl amino 3 methyl 1 oxobutan 2 yl methyl carbamoyl oxy methyl anilino 1 oxopentan 2 yl amino 3 methyl 1 oxobutan 2 yl amino 6 oxohexyl 2 5 dioxopyrrolidin 3 yl vedotin
  • H-gamma1 heavy chain Homo sapiens (1-450) [VH (Homo sapiens IGHV4-39*01 (96.0%) -(IGHD) -IGHJ5*02 (93.8%), CDR-IMGT [10.7.12] (26-35.53-59.98-109)) (1-120) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 D12 (359), L14 (361) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with L-kappa light chain Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01 (96.8%) -IGKJ4*01 (91.7%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, cell line CHO-DG44, glycoform alfa; substituted at the sulfur atoms of four L-cysteinyl residues on an average among 223, 229, 232, 214', 223'', 229'', 232'' and 214''' with a group consisting of (3RS)-1-(6-{[(2S)-1-{[(2S)-5-(carbamoylamino)-1-{4-[({[(2S)-1-{[(2S)-1-{[(3R,4S,5S)-1-{(2S)-2-[(1R,2R)-3-{[(1S,2R)-1-hydroxy-1-phenylpropan-2-yl]amino}-1-methoxy-2-methyl-3-oxopropyl]pyrrolidin-1-yl}-3-methoxy-5-methyl-1-oxoheptan-4-yl](methyl)amino}-3-methyl-1-oxobutan-2-yl]amino}-3-methyl-1-oxobutan-2-yl](methyl)carbamoyl}oxy)methyl]anilino}-1-oxopentan-2-yl]amino}-3-methyl-1-oxobutan-2-yl]amino}-6-oxohexyl)-2,5-dioxopyrrolidin-3-yl (vedotin)
  • immunoglobulin g1 anti human macaca fascicularis mus musculus b7 homolog protein b7h4 human monoclonal b7h41001 γ1 chain disulfide with human monoclonal b7h41001 κ chain dimer reduced tetrakis thioether with n 4 n 6 3 mercapto 2 5 dioxo 1 pyrrolidinyl 1 oxohexyl l valyl n5 aminocarbonyl l ornithyl amino phenyl methoxy carbonyl n methyl l valyl n 1s 2r 4 2s 2 1r 2r 3 1r 2s 2 hydroxy 1 methyl 2 phenylethyl amino 1 methoxy 2 methyl 3 oxopropyl 1 pyrrolidinyl 2 methoxy 1 1s 1 methylpropyl 4 oxobutyl n methyl l valinamide
  • immunoglobulin g1 kappa anti homo sapiens vtcn1 v set domain containing t cell activation inhibitor 1 b7 family member h4 b7h4 b7 h4 homo sapiens monoclonal antibody conjugated on an average of four cysteinyl residues to vedotin comprising a cleavable linker and monomethylauristatin e mmae
  • immunoglobulin G1-kappa, anti-[Homo sapiens VTCN1 (V-set domain containing T cell activation inhibitor 1, B7 family member H4, B7H4, B7-H4)], Homo sapiens monoclonal antibody, conjugated on an average of four cysteinyl residues to vedotin, comprising a cleavable linker and monomethylauristatin E (MMAE);
  • Immunoglobulin G1, anti-(human/Macaca fascicularis/Mus musculus B7 homolog protein B7H4) (human monoclonal B7H41001 γ1-chain), disulfide with human monoclonal B7H41001 κ-chain, dimer, reduced, tetrakis(thioether) with N-[[[4-[[N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]-L-valyl-N5-(aminocarbonyl)-L-ornithyl]amino]phenyl]methoxy]carbonyl]-N-methyl-L-valyl-N-[(1S,2R)-4-[(2S)-2-[(1R,2R)-3-[[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino]-1-methoxy-2-methyl-3-oxopropyl]-1-pyrrolidinyl]-2-methoxy-1-[(1S)-1-methylpropyl]-4-oxobutyl]-N-methyl-L-valinamide

CAS registry numbers
  • 2924808-30-8
ChEMBL ID
CHEMBL6068249
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • VG5Y3A9DFS

First in class
No
Orphan designation
No

Drug name stem
-dotin

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
  • Condition identifier
    MONDO_0005070
  • Condition identifier
    MONDO_0005494
    Highest recorded phase
    1

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    QLQLQESGPGLVKPSETLSLTCTVSGGSIKSGSYYWGWIRQPPGKGLEWIGNIYYSGSTYYNPSLRSRVTISVDTSKNQFSLKLSSVTAADTAVYYCAREGSYPNQFDPWGQGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
  • Component
    Disulfide bridges
    Sequence
    22-97 $ 22''-97'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 147-203 $ 147''-203'' $ 223-214' $ 223''-214''' $ 229-229'' $ 232-232'' $ 264-324 $ 264''-324'' $ 370-428 $ 370''-428''
  • Component
    Light chain
    Type
    Protein
    Sequence
    EIVMTQSPATLSVSPGERATLSCRASQSVSSNLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYHSFPFTFGGGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Glycosylation sites (N)
    Sequence
    300 $ 300''

Related records

Trials (1)

In development for (1)